-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: Some adults with rheumatic and musculoskeletal disorders (RMDs) are at increased risk of COVID-19- related death
.
Excluding the multisystem inflammatory syndrome in children after COVID-19 , children and adolescents were generally less likely to develop severe COVID-19 , and most experienced a mild or asymptomatic course
Objective: Some adults with rheumatic and musculoskeletal disorders (RMDs) are at increased risk of COVID-19- related death
Methods: Using the European Federation of Rheumatology Societies' COVID-19 registry, the Childhood Arthritis and Rheumatism Research Consortium (CARRA) registry, and the CARRA - sponsored COVID-19 Global Pediatric Rheumatology Database, we obtained data on children and adolescents with RMD .
SARS-CoV-2 infection (presumptive or confirmed) data .
Patient characteristics and disease severity were described, and factors associated with hospitalization for COVID-19 were investigated .
RESULTS: Included 607 children and adolescents with RMD <19 years from 25 different countries infected with SARS-CoV-2 , most of whom had juvenile idiopathic arthritis ( JIA ; n=378 ; 62% ) .
Forty -three (7%) patients were hospitalized; three of these patients died .
Diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis or other RMD ( OR 4.
RESULTS: Included 607 children and adolescents with RMD <19 years from 25 different countries infected with SARS-CoV-2 , most of whom had juvenile idiopathic arthritis ( JIA ; n=378 ; 62% ) .
Forty -three (7%) patients were hospitalized; three of these patients died .
Diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis or other RMD ( OR 4.
3 ; 95% CI 1.
Conclusions: This is the leading investigation to date of COVID-19 infection among children and adolescents with RMD .
Notably, most children and adolescents were not hospitalized with COVID-19 , although those with severe systemic RMD and obesity were more likely to be hospitalized .
Source: Kearsley-Fleet L, Chang M, Lawson-Tovey S , et al.
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases.
Annals of the Rheumatic Diseases Published Online First: 25 March 2022.
doi: 10.
Source: Kearsley-Fleet L, Chang M, Lawson-Tovey S , et al.
, et al.
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases.
Annals of the Rheumatic Diseases Annals of the Rheumatic Diseases Published Online First: 25 March 2022.
doi: 10.
1136/annrheumdis-2022-222241 Leave a comment here
